Get the Stockscreener App
1.26
5.88%
0.07
Pre-market:
1.23
-0.03
-2.38%
Moleculin Biotech Inc stock is traded at $1.26, with a volume of 720.45K.
It is up +5.88% in the last 24 hours and up +200.00% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$1.19
Open:
$1.19
24h Volume:
720.45K
Relative Volume:
0.14
Market Cap:
$15.13M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0824
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+8.62%
1M Performance:
+200.00%
6M Performance:
-48.15%
1Y Performance:
-85.03%
1-Day Range:
$1.1795
$1.32
1-Week Range:
$1.043
$1.32
52-Week Range:
$0.3975
$8.85
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
1.26 | 15.13M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - Star Local Media
Moleculin to Present at the 37th Annual ROTH Conference - StockTitan
Moleculin to Present at the 37th Annual ROTH Conference -March 10, 2025 at 08:46 am EDT - Marketscreener.com
Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech - openPR
Moleculin Announces Additional Annamycin Patent Allowances to En - GuruFocus.com
Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity - Marketscreener.com
Moleculin Biotech to be granted new patents for Annamycin - TipRanks
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - The Malaysian Reserve
What is HC Wainwright’s Forecast for MBRX Q4 Earnings? - Defense World
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Receives Positive FDA Guidance for Acceleration of its - GuruFocus.com
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Moleculin Biotech’s (MBRX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium - Marketscreener.com
Buy Rating for Moleculin Biotech: Accelerated Annamycin Development and Strategic Advancements - TipRanks
Moleculin stock target cut to $8 at H.C. Wainwright By Investing.com - Investing.com Canada
Moleculin stock target cut to $8 at H.C. Wainwright - Investing.com India
SEC Form 424B5 filed by Moleculin Biotech Inc. - Quantisnow
Moleculin Biotech secures $3.5 million in stock and warrant sale By Investing.com - Investing.com Australia
Moleculin Biotech Prices $3.5 Million Direct Offering; Shares Rise -February 25, 2025 at 01:07 pm EST - Marketscreener.com
Moleculin Biotech secures $3.5 million in stock and warrant sale - Investing.com
Moleculin Biotech announces pricing of $3.5M registered direct offering - TipRanks
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules - Finansavisen
Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World
MGO Global, Moleculin Biotech, and Sacks Parente Golf Lead Penny Stock Surge - PUNE.NEWS
Moleculin Announces FDA Guidance for MIRACLE Trial Acceleration in Relapsed or Refractory AML - DocWire News
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Armenian Reporter
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech (NASDAQ:MBRX) Enters Into Warrant Exercise Inducement Agreement - Defense World
Moleculin Biotech Receives FDA Guidance for Phase 3 Trial on Annamycin-Cytarabine Combination - Defense World
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - The Malaysian Reserve
Moleculin Biotech secures $5.8 million from warrant exercise - MSN
Moleculin Biotech stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants -February 13, 2025 at 01:33 pm EST - Marketscreener.com
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? - Benzinga
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Stock market news: Tantech Holdings declined by 97.05% while Moleculin Biotech surged by 590.48% during midday trading - Business Upturn
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine - MSN
Moleculin (MBRX) Stock Rallies On Positive Regulatory Developments - Stocks Telegraph
Moleculin's Phase 3 AML trial gets FDA nod for size reduction - Investing.com
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
Stock market today: Tantech Holdings declined by 97.39% while Moleculin Biotech surged by 354.76% in early trading - Business Upturn
Moleculin Biotech Gets FDA Nod for Phase 3 Trial - TipRanks
Moleculin Biotech receives positive FDA guidance for acceleration of AML trial - TipRanks
Moleculin Receives Positive FDA Guidance For Its Trial For R/R Acute Myeloid Leukemia - Marketscreener.com
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) – Company AnnouncementFT.com - Financial Times
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy? - AOL
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) - Finansavisen
Moleculin Biotech (NASDAQ:MBRX) Receives First Country Regulatory Approval in Europe for Phase 3 Clinical Trial Protocol for Annamycin Combination - Defense World
Moleculin Biotech stock hits 52-week low at $0.5 - Investing.com India
Moleculin Announces First European Approval for Phase 3 AML Trial By Investing.com - Investing.com Nigeria
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):